Bristol-Myers Squibb (BMY) Affirms FDA Expanded Approval of Opdivo as Treatment of Certain cHL
Tweet Send to a Friend
Bristol-Myers Squibb Company (NYSE: BMY) announced the U.S. Food and Drug Administration (FDA) has approved Opdivo® (nivolumab) for the treatment ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
